

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1498)**

**SUPPLEMENTAL AGREEMENT  
IN RELATION TO THE ACQUISITION OF THE TARGET COMPANIES**

Reference is made to the announcement of the Company dated 9 November 2016 and the circular of the Company dated 30 December 2016 (the “**Circular**”). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

With a view to providing sufficient flexibility to the Group to determine its organisational structure in order to meet its long term development strategy, on 17 February 2017 (after trading hours of the Stock Exchange), PuraPharm (Nanning) Pharmaceuticals Co. Limited (培力(南寧)藥業有限公司) (“**PuraPharm Nanning**”), an indirect wholly-owned subsidiary of the Company, as the purchaser to the Acquisition Agreement, and Gold Sparkle Plantation Company Limited (“**Gold Sparkle**”) as the vendor to the Acquisition Agreement entered into a supplemental agreement to the Acquisition Agreement (the “**Supplemental Agreement**”), pursuant to which the parties agreed to amend and extend the purchaser to the Acquisition to include PuraPharm Nanning or its nominee which shall be a wholly-owned subsidiary of the Company (the “**Nominee**”) and the cash consideration of the Acquisition shall be settled by PuraPharm Nanning or the Nominee, as the case maybe, accordingly.

The Board considers that the terms of the Supplemental Agreement are fair and reasonable and the entering into of the Supplemental Agreement is in the interests of the Company and the Shareholders as a whole.

Save for the amendments disclosed above and the corresponding amendments thereto, all other principal terms and conditions of the Acquisition Agreement remain unchanged and continue in full force and effect. There has been no material change to the structure of the transaction which may cause any material impact to the Acquisition or may possibly affect the completion of the Acquisition.

**Completion of the Acquisition is subject to the conditions precedent under the paragraph headed “Conditions precedent of the Acquisition” in the Circular, which may or may not be fulfilled. The Acquisition may or may not proceed. Shareholders and potential investors of the Company should exercise caution when they deal or contemplate dealing in the Shares and other securities of the Company.**

By order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 17 February 2017

*As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Lung Sang and Ms. Man Yee Wai, Viola; the non-executive director of the Company is Mr. Chan Kin Man, Eddie; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*